CRA consultants analyzed market power and alleged anticompetitive conduct for a CNS therapy. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing. Also considered were effects on demand resulting from the change in the form of competition upon the launch of generic products.
SEP licensing in the United States: Understanding the impact on US business
US Business Survey On behalf of ACT | The App Association, consultants with Charles River Associates undertook a survey of US businesses that use technical...